ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$292.01
+2.10%Year over year
Reported trailing growth
- Revenue
- +10.7%
- EBITDA
- +88.7%
- EBIT
- +159.5%
- EPS
- +337.9%
- Free cash flow
- -9.5%
- Operating cash flow
- -8.8%
Forward estimates
Based on analyst estimates
- Revenue
- +8.3%
- EBITDA
- +76.7%
- EPS
- +169.9%
Three-year CAGR
- Revenue
- +1.8%
- EBITDA
- -10.0%
- EBIT
- +3.5%
- Net income
- -29.1%
- EPS
- -29.1%
- Free cash flow
- -9.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026